MedTrace Logo

Comparison of the Efficacy and Safety of Duloxetine Augmented With Gabapentin and Duloxetine Augmented With Amitriptyline vs Duloxetine Alone in Chemotherapy -Induced Neuropathy

NCT06091553 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2024-04-16

No results posted yet for this study

Summary

This study aimed to elucidate the relationship between the Efficacy and Safety of Comparison of the Efficacy and Safety Duloxetine augmented with gabapentin and amitriptyline augmented with Duloxetine vs duloxetine alone in chemotherapy -Induced Neuropathy in cancer patients.

Conditions

  • Neuropathy in Cacer Patien

Interventions

DRUG

Duloxetine alone

30 mg once daily for 1 week, then 60 mg once daily

DRUG

Duloxetine augmented with gabapentin

30 mg once daily for 1 week, then 60 mg once daily 300 mg at bedtime

DRUG

Duloxetine augmented with amitriptyline (as combined therapy)

10 to 25 mg once daily at bedtime 30 mg once daily for 1 week, then 60 mg once daily

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-10
Primary Completion
2024-09-30
Completion
2024-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06091553 on ClinicalTrials.gov